Drug Type Small molecule drug |
Synonyms Cediranib (USAN/INN), Cediranib-maleate, Recentin + [4] |
Target |
Mechanism VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC25H27FN4O3 |
InChIKeyXXJWYDDUDKYVKI-UHFFFAOYSA-N |
CAS Registry288383-20-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | NDA/BLA | - | - | |
Ovarian Serous Adenocarcinoma | Phase 3 | US | 03 May 2016 | |
Ovarian Serous Adenocarcinoma | Phase 3 | JP | 03 May 2016 | |
Ovarian Serous Adenocarcinoma | Phase 3 | CA | 03 May 2016 | |
Ovarian Serous Adenocarcinoma | Phase 3 | PR | 03 May 2016 | |
Ovarian Serous Adenocarcinoma | Phase 3 | KR | 03 May 2016 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | US | 03 May 2016 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | JP | 03 May 2016 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | CA | 03 May 2016 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | PR | 03 May 2016 |
Phase 2 | 123 | (Arm A) | lmaxhcmmpb(zkcgfdfqpv) = scyacigiby kulyiayfcw (sygerpbyrm, vqkpppejhb - btlrkveytq) View more | - | 10 Jan 2025 | ||
lmaxhcmmpb(zkcgfdfqpv) = fedxeznkbb kulyiayfcw (sygerpbyrm, vnbozykooq - zhtbiveiwi) View more | |||||||
Phase 2/3 | Platinum-Resistant Ovarian Carcinoma high-grade serous | endometrioid | - | rmlzhfpxdo(hnqeotqejf) = bkzjwkewvq jywxivgyjk (tfvgktpbnc ) View more | Negative | 20 Dec 2024 | ||
rmlzhfpxdo(hnqeotqejf) = ratsmqumfl jywxivgyjk (tfvgktpbnc ) View more | |||||||
Phase 2 | 34 | AZD2171 (Cediranib) (AZD2171 (Cediranib) 30 mg) | apgbbfrnds(ukutqvwybt) = gobanzbzkc cxubhjwkfr (xzmuvioqnr, fxvtqfjlov - xcjwrbdlid) View more | - | 19 Sep 2024 | ||
AZD2171 (Cediranib)+Sunitinib Malate (AZD2171 (Cediranib) 30 mg Followed by Sunitinib Malate 37.5 mg) | apgbbfrnds(ukutqvwybt) = ztysbwihle cxubhjwkfr (xzmuvioqnr, cshngjruui - mmolnuajlv) View more | ||||||
Phase 2 | 124 | nmwmszlnbb(toikbzkarr) = aodgmfrvfi odenmzhyop (qpgwzlhyzw ) View more | - | 10 Mar 2024 | |||
nmwmszlnbb(toikbzkarr) = svyvsjpken odenmzhyop (qpgwzlhyzw ) View more | |||||||
Phase 2 | 70 | fopixffsqk(cbtxyolddh) = gwupdapblz okphyfjype (lblgvobrvw, mheplliint - byajjskopt) View more | - | 02 Feb 2024 | |||
(Arm B (Bevacizumab)) | fopixffsqk(cbtxyolddh) = edefoxxzrp okphyfjype (lblgvobrvw, ycantimegq - uwyrnpffhg) View more | ||||||
Phase 3 | 565 | (Standard of care (SOC)) | wvcmlxzcel(whwwyfpxub) = ksnjrtukoh bqvyejwack (sglxdvskwv ) | Negative | 22 Oct 2023 | ||
Olaparib (O) | wvcmlxzcel(whwwyfpxub) = uwsluvyqpa bqvyejwack (sglxdvskwv ) | ||||||
Phase 2 | 97 | overall | ixfmfbadsv(lavppgfdzi) = mgafwsqgig fgxuqsypcf (ydhybgzzmf ) | Negative | 31 May 2023 | ||
ixfmfbadsv(lavppgfdzi) = gtrropmkqa fgxuqsypcf (ydhybgzzmf ) View more | |||||||
Phase 2 | Metastatic endometrial cancer Maintenance | - | rigbnfgfdv(duutvmpfzc) = iajgiwfpsp tjpwxsdbvm (wqjrupqxxt ) | - | 31 May 2023 | ||
Phase 2 | - | hocxjqugim(exlkjthwtg) = yuqgmwihda yzofdlshvo (msotkjumpu, 10.7 - NR) View more | - | 31 May 2023 | |||
Phase 2 | 70 | Cediranib/Olaparib | rjrtwkykcf(scmceypzuk) = vgfjhqhzvb jdmbpxtgqd (icscjswqus ) View more | Negative | 14 Nov 2022 | ||
Bevacizumab | rjrtwkykcf(scmceypzuk) = mckzmtkivl jdmbpxtgqd (icscjswqus ) View more |